Showing results (101-110 of 179) with videos related to
Sort By:
Pageof 18
JACC. Cardiovascular Imaging|May 19, 2012
Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivoJan Bucerius, Christoph Manka, Jörn Schmaljohann, et al.Pulmonary Circulation|April 25, 2012
(18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle studyGuy Hagan, Mark Southwood, Carmen Treacy, et al.Circulation. Cardiovascular Imaging|August 21, 2013
Atherosclerotic plaque composition and classification identified by coronary computed tomography: assessment of computed tomography-generated plaque maps compared with virtual histology intravascular ultrasound and histologyDaniel R Obaid, Patrick A Calvert, Deepa Gopalan, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2008
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendationsJames H F Rudd, Kelly S Myers, Sameer Bansilal, et al.JACC. Cardiovascular Imaging|January 14, 2012
Correlation between arterial FDG uptake and biomarkers in peripheral artery diseaseKelly S Myers, James H F Rudd, Eric P Hailman, et al.Circulation. Cardiovascular Imaging|July 20, 2010
Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot studyRamez Reda Moustafa, David Izquierdo-Garcia, Tim D Fryer, et al.Stroke|November 12, 2005
Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imagingJohn R Davies, James H F Rudd, Tim D Fryer, et al.Journal of the American College of Cardiology|June 2, 2010
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time?James H F Rudd, Jagat Narula, H William Strauss, et al.Atherosclerosis|March 11, 2015
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndromeJuan Gaztanaga, Michael Farkouh, James H F Rudd, et al.Health Technology Assessment (Winchester, England)|February 1, 2019
Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCTJohn Strang, Michael Kelleher, Soraya Mayet, et al.Pageof 18